Phase 1 Study Evaluating the Safety and Tolerability of BHV-7000, a Novel, Selective Kv7.2/7.3 Potassium Channel Activator, in Healthy Adults (P8-1.007)
Key points are not available for this paper at this time.
Abstract
Evaluate the safety and tolerability of single and multiple ascending doses (SAD and MAD) of oral BHV-7000.
AIに質問
Like
Bookmark
Share
View Full Paper
AIに質問
Like
Bookmark
Share
View Full Paper
Phase 1 Study Evaluating the Safety and Tolerability of BHV-7000, a Novel, Selective Kv7.2/7.3 Potassium Channel Activator, in Healthy Adults (P8-1.007) | Synapse